Commercial Manufacturing
Capabilities
Manufacturing of Regulatory starting materials, APIs, HPAPI, NCEs & Novel advanced intermediates
DOWNLOAD TO LEARN MORE>>>>
DOWNLOAD TO LEARN MORE>>>>
Literature / Brochures
Commercial Manufacturing
Syngene supports manufacturing of regulatory starting materials, APIs, HPAPI, NCEs and novel advanced intermediates.
More Literature / Brochures by Syngene
-
Brochures
Targeted Protein Degradation
Syngene has considerable experience solving synthetic chemistry and purification challenges with PROTACS.359357 01.18.21
-
Brochures
Biologics and Manufacturing
Syngene offers Biologics development and Biomanufacturing solutions in both mammalian and microbial systems.359346 01.15.21
-
Brochures
Chemical Development
Syngene has full value-chain Process Research and Development (PRD) capabilities for NCEs and advanced intermediates.359349 01.14.21
-
Brochures
Clinical Development
Syngene supports early-phase to late-phase clinical trials required for drug development programs across a wide range of therapeutic areas.359351 01.13.21
-
Brochures
Formulation Development
Syngene supports both development and manufacturing of Drug Products from early to late stage.359354 01.11.21
-
Brochures
ICH Stability Studies
One of the largest Stability facilities in Asia, Syngene supports both small and large molecules from early development to CMC filing and commercialization.359355 01.08.21
-
Brochures
Oligonucleotides
Syngene's services encompass Therapeutic oligonucleotides, Diagnostic Oligonucleotides, Enzymatic synthesis and analytical services.359356 01.07.21
More Content From Syngene
-
Your Pre-clinical Toxicology Program Needs a Strategy
At Syngene, we have developed a roadmap across pre-IND, IND and NDA that seamlessly integrate the various pre-clinical studies.Case Studies Released on 01.14.2021
-
The Dedicated Center
Outsourcing answer to the innovation and ROI challenge in the Biopharmaceutical Industry.Case Studies Released on 01.13.2021
-
Proactive COVID-19 Testing
By identifying COVID-19 positive cases early on, particularly those that are asymptomatic, we can restrict further transmission of this deadly virus.Case Studies Released on 01.12.2021
-
How Integrated CMC Can Help Expedite Early Phase Development of Small Molecules – A CRO Perspective
Syngene's 7-phase integrated CMC strategy helps expedite IND/IMPD filings and FIH studies.Case Studies Released on 01.11.2021
-
Harnessing Targeted Protein Degradation
Read how Syngene's partnership with a leading Biotech company working in the field of cancer therapy grew from one small pilot project to over 100 FTEs today.Case Studies Released on 01.08.2021
-
The Many Benefits of Outsourcing Stability: A Baxter-Syngene Case study
Learn why Baxter chose to partner with Syngene for Stability studies, the business flow, governance mechanism and metrics that were implemented.Case Studies Released on 01.07.2021
-
Syngene and Deerfield Discovery and Development (3DC) sign 5-year strategic collaboration
...News Releases Released on 11.19.2020
-
Syngene eases clients’ path to drug discovery
Anil Urs - BengaluruNews Releases Released on 10.30.2020
-
Syngene International Q2 profit up 64 pc to Rs 128 cr
Press Trust of India | New DelhiNews Releases Released on 10.22.2020
-
Syngene joins global consortium to accelerate research in COVID-19 testing
The consortium brings together a diverse group of companies with synergistic areas of expertiseNews Releases Released on 10.02.2020
